Outcomes in patients with peripheral T-cell lymphomas are poor and there are no established standards of care for patients in the relapsed and refractory setting, owing in part to the lack of multicenter, controlled clinical trials. Recently, encouraging results were reported in this setting with pralatrexate—a novel folate analog.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Therapeutic options in peripheral T cell lymphoma
Journal of Hematology & Oncology Open Access 12 April 2016
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Vose, J. et al. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J. Clin. Oncol. 26, 4124–4130 (2008).
Schmitz, N. et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood 116, 3418–3425 (2010).
Delmer, A. et al. A phase II study of bortezomib in combination with intensified CHOP-like regimen (ACVBP) in patients with previously untreated T-cell lymphoma: results of the GELA LNH05–01T trial [abstract]. J. Clin. Oncol. 27 (15 Suppl.), a8554 (2009).
Reimer, P. et al. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J. Clin. Oncol. 27 106–113 (2009).
Rodríguez, J. et al. The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: the Spanish Lymphoma and Autologous Transplantation Group experience. Ann. Oncol. 18, 652–657 (2007).
D'Amore, F. et al. Dose-dense induction followed by autologous stem cell transplant (ASCT) leads to sustained remissions in a large fraction of patients with previously untreated peripheral T-cell lymphomas (PTCLs)—overall and subtype-specific results of a phase II study from the Nordic Lymphoma Group. Haematologica 94 (Suppl. 2), a437 (2009).
O'Connor, O. A. et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J. Clin. Oncol. 29, 1182–1189 (2011).
O'Connor, O. A. et al. Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies. J. Clin. Oncol. 27, 4357–4364 (2009).
Piekarz, R. L. et al. Phase II trial of romidepsin in patients with peripheral T-cell lymphoma. Blood doi:10.1182/blood-2010-10-312603.
Coiffier, B. et al. Final results from a pivotal, multicenter, international, open-label, phase 2 study of romidepsin in progressive or relapsed peripheral T-cell lymphoma (PTCL) following prior systemic therapy [abstract]. Blood 116, a114 (2010).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
F. Foss is a consultant for and receives honoraria from Allos, Celgene and Eisai. She is a consultant for and receives research support from Merck and she receives honoraria from Cephalon.
Rights and permissions
About this article
Cite this article
Foss, F. Relapsed and refractory PTCL—into the therapeutic abyss. Nat Rev Clin Oncol 8, 321–322 (2011). https://doi.org/10.1038/nrclinonc.2011.51
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2011.51
This article is cited by
-
Prognostic value of 18F-FDG lesion dissemination features in patients with peripheral T-cell lymphoma (PTCL)
Japanese Journal of Radiology (2023)
-
Allogeneic stem cell transplantation for patients with relapsed or refractory T-cell lymphoma: efficacy of lymphoma-directed conditioning against advanced disease
Bone Marrow Transplantation (2019)
-
Therapeutic options in peripheral T cell lymphoma
Journal of Hematology & Oncology (2016)